ALK-Abelló and Schering-Plough have signed an agreement on a strategic alliance to develop and commercialize ALK-Abelló's tablet-based immunotherapies against grass pollen allergy (GRAZAX®), house dust mite allergy and ragweed allergy for the North American market.